Mar 23, 2026 07:45AM TuHURA names former J&J oncology executive as chief medical officer

Feb 17, 2026 07:46AM TuHURA files drug application for blood cancer treatment

Feb 2, 2026 07:45AM TuHURA Biosciences receives FDA orphan drug designation for melanoma treatment

Dec 15, 2025 07:51AM TuHURA to distribute shares to CVR holders after Kintara trial milestone

Dec 11, 2025 07:30AM TuHURA Biosciences raises $15.6 million in equity financing

Dec 8, 2025 07:50AM TuHURA Biosciences presents cancer immunotherapy research at ASH meeting

Nov 14, 2025 07:50AM TuHURA Biosciences (HURA) Misses Q3 EPS by 14c

Nov 3, 2025 09:02AM TuHURA Biosciences presents cancer immunotherapy research at ASH meeting

Aug 22, 2025 06:58AM H.C. Wainwright Reiterates Buy Rating on TuHURA Biosciences (HURA)

Jul 1, 2025 08:50AM TuHURA Biosciences (HURA) added to Russell 2000 and 3000

Jun 30, 2025 08:51AM TuHURA Biosciences (HURA) completes Kineta (KANT) acquisition

Jun 30, 2025 06:52AM H.C. Wainwright Reiterates Buy Rating on TuHURA Biosciences (HURA)

Jun 24, 2025 08:04AM TuHURA Biosciences (HURA) Initiates Its Phase 3 Accelerated Approval Trial of IFx-2.0 as an Adjunctive Therapy to Keytruda® (pembrolizumab) in First Line Treatment for Advanced or Metastatic Merkel C

Jun 23, 2025 05:02PM TuHURA Biosciences (HURA) and Kineta (KANT) Receive Stockholders Approval of Proposed Merger and All Related Proposals

Jun 23, 2025 09:16AM Brookline Capital Markets Starts TuHURA Biosciences (HURA) at Buy

Jun 9, 2025 10:12AM TuHURA Biosciences (HURA) stock rises following FDA hold lift

Jun 9, 2025 08:01AM TuHURA Biosciences (HURA) Says FDA Removed Partial Clinical Hold on Phase 3 Accelerated Approval Trial for IFx-2.0

Jun 3, 2025 10:00AM TuHURA Biosciences (HURA) Enters into $12.5M Equity Financing Transaction, Receives $3M in Warrant Exercise Proceeds

May 5, 2025 08:06AM TuHURA Biosciences (HURA) Initiates Phase 1b/2a Study of IFx-Hu2.0 as an Adjunctive Therapy to Keytruda in First Line Treatment for MCCUP

Apr 28, 2025 08:04AM TuHURA Biosciences (HURA) and Kineta Present Updated Results from Kineta's Phase I-II Study of KVA12123

Apr 7, 2025 08:25AM TuHURA Biosciences (HURA) Appoints Dr. Bertrand Le Bourdonnec as Executive Vice President, Head of Drug Discovery, Early Development, and Program Management

Apr 3, 2025 06:45AM TuHURA Biosciences (HURA) PT Lowered to $12 at H.C. Wainwright

Mar 11, 2025 08:05AM TuHURA Biosciences, Inc Appoints Craig L. Tendler M.D., Former Vice President, Oncology Clinical Development, Diagnostics, and Global Medical Affairs, Johnson & Johnson Innovative Medicine Research &

Mar 10, 2025 09:00AM TuHURA Biosciences, Inc. to Present at the 37th Annual ROTH Conference

Feb 19, 2025 09:00AM TuHURA Biosciences, Inc. Participates in the Virtual Investor “Top 5 for ‘25” On-Demand Conference

Dec 19, 2024 05:48AM Rodman & Renshaw Starts TuHURA Biosciences (HURA) at Buy

Dec 13, 2024 01:21PM SHAREHOLDER ALERT: Rigrodsky Law, P.A. Is Investigating TuHURA Biosciences, Inc. Merger

Dec 12, 2024 08:46AM TuHURA Biosciences (HURA) Enters into Definitive Merger Agreement to Acquire Kineta, Inc.

Dec 12, 2024 08:45AM TuHURA Biosciences, Inc. Enters into Definitive Merger Agreement to Acquire Kineta, Inc.

Nov 25, 2024 08:39AM TuHURA Biosciences (HURA) Outlines Development Pathway for Single Phase 3 Accelerated Approval Registration Trial in First Line Treatment of Advanced or Metastatic Merkel Cell Carcinoma

Nov 25, 2024 08:35AM TuHURA Biosciences, Inc. (Nasdaq: HURA) Outlines Development Pathway for Single Phase 3 Accelerated Approval Registration Trial in First Line Treatment of Advanced or Metastatic Merkel Cell Carcinoma

Oct 23, 2024 08:30AM TuHURA Biosciences (Nasdaq: HURA) Announces Webcast Replay of Panel Presentation at the 2024 Maxim Healthcare Virtual Summit, Presented by Maxim Group LLC

Oct 22, 2024 09:00AM TuHURA Biosciences (NASDAQ:HURA) to Present at the Virtual Investor "New to the Street" Event

Oct 17, 2024 04:38PM TuHURA Biosciences (HURA) Completes Merger Transaction with Kintara Therapeutics

Oct 17, 2024 04:35PM TuHURA Biosciences Completes Merger Transaction with Kintara Therapeutics